Celltrion Will Trial COVID-19 Antiviral From July
Company Identifies 14 Antibodies Most Potent For Neutralizing Coronavirus
Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.
You may also be interested in...
In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.